The influence of omeprazole and pantoprazole on the platelet reactivity and inhibition of platelet aggregration of clopidogrel.

The influence of omeprazole and pantoprazole on the platelet reactivity and inhibition of platelet aggregration of clopidogrel. - The influence of omeprazole and pantoprazole on the activity of clopidogrel

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32694

Enrollment

Registered

2010-01-25

Start date

2010-05-10

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Activity of clopidogrel prophylaxis against NSAID induced gastric damage

Interventions

Replacing of omeprazole by pantoprazole for 4 weeks.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Use of clopidogrel and aspirin or carbasalate calcium. 2. Use of omeprazole as prophylaxis against NSAID induced gastric damage. 3. Written informed consent. 4. 18 years or older.

Exclusion criteria

Exclusion criteria: 1. Use of medication which affects the metabolism of clopidogrel 2. Severe adverse reaction or hypersensitivity reaction to pantoprazole. 3. Gastrointesnital ulcer. 5. Renal impairment (creatinine> 200 mmol/l). 6. liver disease (AST, ALT, GGT> 3 x ULN). 7. Pregnancy

Design outcomes

Primary

Measure	Time frame
1. The platelet reactivity index 2. The inhibition of platelet aggregation	—

Secondary

Measure	Time frame
Side effects of pantoprazole.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)